A groundbreaking study from Duke Health harnesses the power of AI to analyze routine electronic health records (EHRs) and estimate the risk of ADHD well before conventional clinical diagnosis occurs. The study, published in Nature Mental Health, dives deep into the wealth of clinical data accumulated in primary care settings. Researchers developed a sophisticated AI model trained on EHR data from more than 140,000 children, effectively unlocking hidden patterns across developmental, behavioral, and clinical parameters from birth through early childhood.

This AI-based predictive model is not a diagnostic instrument per se but functions as a risk stratification tool. It sifts through vast repositories of medical histories, identifying subtle, intricate interplays of variables that often presage an eventual ADHD diagnosis. Importantly, the model exhibits high predictive accuracy from the age of five onwards, maintaining robust performance across diverse demographics including sex, race, ethnicity, and insurance status. This generalizability marks a significant advance over previous attempts that often struggled with bias or limited datasets.

The transformative potential of such an AI-driven approach lies in its capacity to propel ADHD assessment into a proactive phase rather than reactive recognition. Typically, children with ADHD are diagnosed only after years of behavioral challenges and academic struggles. Early risk estimation equips pediatricians and primary care providers with actionable alerts, empowering them to closely monitor at-risk children and initiate timely referrals for comprehensive diagnostic evaluations by specialists.

Elliot Hill, the study’s lead author and a data scientist at Duke’s Department of Biostatistics & Bioinformatics, emphasizes the untapped richness of electronic health records. The AI effectively distills complex clinical narratives into predictive insights, demonstrating that everyday medical data can yield powerful prognostic signals that were previously inaccessible. Rather than creating an AI “doctor,” the model serves as an assistive technology aimed at optimizing clinician workflow and resource allocation.

Matthew Engelhard, M.D., Ph.D., the study’s senior author, underscores that automated tools like this could prevent many children from “falling through the cracks.” By spotlighting those who are at heightened risk, clinicians can allocate more focused attention and deploy evidence-based interventions sooner, which is strongly correlated with enhanced academic and psychosocial outcomes.

From a technical perspective, the AI model employs advanced machine learning techniques capable of integrating vast multidimensional data points, including developmental milestones, recorded behavioral issues, comorbid medical conditions, and even patterns indicating healthcare utilization. This holistic analysis leverages longitudinal data, allowing the system to discern trajectories rather than relying on static snapshots, which greatly enhances prediction accuracy.

Despite these promising results, the researchers caution that the AI tool requires further validation before widespread clinical adoption. Rigorous prospective studies and real-world trials are necessary to assess effectiveness, safety, and ethical implications. Additionally, integration within existing healthcare infrastructures presents logistical challenges, including data standardization, patient privacy considerations, and interoperability with diverse EHR systems.

Naomi Davis, Ph.D., an associate professor in the Department of Psychiatry and Behavioral Sciences and co-author, highlights the critical importance of connecting at-risk families with timely, evidence-based supports. Early identification must be paired with adequate resources and interventions tailored to each child’s unique needs, or else the benefits of predictive technology risk being lost.

This research aligns with a larger movement harnessing AI to predict and understand mental health risks across the lifespan. Hill and Engelhard have contributed additional studies exploring AI applications in adolescent mental illness, illustrating a growing commitment to integrating computational models into psychiatric epidemiology and personalized medicine.

The study benefits from robust funding by the National Institute of Mental Health and the National Center for Advancing Translational Sciences, signaling strong institutional support for leveraging AI as a transformative force in medical diagnostics. As the field continues to innovate, such AI-driven models may soon be integral to pediatric care, enabling clinicians to anticipate disorders like ADHD with unprecedented precision and intervene at life-changing early stages.

In summary, this pioneering work demonstrates that AI tools analyzing routine clinical data can efficiently predict ADHD risk long before traditional diagnoses arise. By embedding such technologies into everyday healthcare workflows, there is a distinct possibility of drastically transforming outcomes and quality of life for millions of children worldwide, delivering on the promise of precision medicine tailored from the very start of life.

Subject of Research: Early prediction of attention-deficit/hyperactivity disorder (ADHD) risk in children through artificial intelligence analysis of electronic health records

Article Title: Artificial Intelligence Models Predict Childhood ADHD Risk Years Before Diagnosis Using Routine Electronic Health Records

News Publication Date: April 27, 2026

Web References: https://www.nature.com/articles/s44220-026-00628-2

Image Credits: Duke Health / Shawn Rocco

Keywords

Attention-deficit/hyperactivity disorder, ADHD, artificial intelligence, AI, electronic health records, EHR, pediatric medicine, early diagnosis, machine learning, neurodevelopmental disorders, predictive modeling, mental health

The research, slated for publication in the August 29 issue of JAMA Network Open, analyzed health data drawn from nearly 10,000 preschool-aged children diagnosed with ADHD across eight pediatric health networks in the United States. The study’s findings reveal that over 40% of these young patients were prescribed stimulant medications within just one month of receiving their ADHD diagnosis. This rapid prescription pattern deviates sharply from clinical guidelines that emphasize behavioral therapies as the first line of treatment in this vulnerable age group.

Behavioral therapy, particularly parent training in behavior management, is designed to modify the child’s environment and parental responses to ADHD-related behaviors. This evidence-based approach fosters skill-building within families, helping parents establish consistent routines and reinforcing positive behavior strategies. It is a non-invasive modality aiming to harness neurodevelopmental plasticity during early childhood, thereby potentially altering the long-term trajectory of ADHD symptoms without immediate reliance on medication.

In contrast, the commonly prescribed stimulant medications act by modulating neurotransmitter systems to alleviate core symptoms such as hyperactivity and inattention. However, these medications have a relatively short duration of action, necessitating careful dosing schedules, and their pharmacokinetics in very young children are notably different. Young children metabolize these drugs less efficiently than older children, increasing the likelihood of side effects, which can include irritability, emotional instability, and aggression. Such adverse reactions often undermine adherence and can lead families to discontinue medication prematurely.

ADHD, a neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity, often manifests early in life and can adversely affect academic and social outcomes if untreated or inadequately managed. Early diagnosis is crucial, as untreated ADHD is associated with increased risk for academic underachievement, social difficulties, and later life challenges including impaired occupational functioning and increased legal troubles. Yet, the optimal management strategy during the preschool years remains a nuanced challenge for clinicians and families alike.

The study’s large-scale data analysis uncovered that children who received a formal ADHD diagnosis were more likely to be prescribed medication quickly compared to those with only recorded symptoms suggestive of ADHD initially. Interestingly, even among children not meeting full diagnostic criteria at first, nearly a quarter still received stimulant medications within 30 days. These patterns indicate a possible inclination toward pharmacotherapy driven by clinical urgency or lack of access to behavioral treatment resources rather than strict adherence to guideline-recommended care pathways.

One of the salient barriers identified by the researchers in informal conversations with pediatricians is the limited availability of behavioral therapy. Access issues stem from a shortage of qualified therapists, insurance coverage limitations, and geographic disparities. Consequently, primary care providers sometimes resort to prescribing medication as an expedient alternative when non-pharmacologic treatments are inaccessible. This pragmatic, although guideline-divergent, approach highlights systemic gaps in the healthcare infrastructure related to early ADHD management.

The implications of this study are profound, suggesting an urgent need to bridge the divide between recommended care and clinical practice. Educational initiatives targeting primary care providers could enhance awareness about the importance of behavioral interventions as initial treatment. Moreover, increasing the accessibility of behavioral management resources, including free or low-cost online programs, may empower families and clinicians to adhere more closely to best practice models, ensuring safer and more effective care for young children with ADHD.

Furthermore, the research underscores that beyond the preschool years, an integrative treatment model combining behavioral therapy and medication tends to yield the best outcomes. Behavioral therapy imparts long-term skills for managing symptoms and improving executive functioning, which medication alone cannot achieve. Thus, even as children grow older, a multidisciplinary treatment approach remains essential to optimize developmental trajectories and life-long success.

Methodologically, the study employed rigorous data and statistical analysis leveraging PEDSnet, a large-scale pediatric clinical research network. This comprehensive dataset from multiple top-tier academic medical centers enables a robust assessment of real-world prescribing patterns, offering valuable insights into current clinical trends and their alignment with established guidelines.

Ultimately, this research calls for a paradigm shift in addressing the management of very young children diagnosed with ADHD. Prioritizing early behavioral interventions and addressing structural barriers to their implementation could dramatically improve outcomes while minimizing unnecessary exposure to stimulant medications during a critical neurodevelopmental window. As our understanding of ADHD’s developmental course evolves, so too must our commitment to evidence-based, patient-centered care.

Subject of Research: People
Article Title: ADHD Diagnosis and Timing of Medication Initiation Among Children Aged 3 to 5 Years
News Publication Date: 29-Aug-2025
Web References: http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.29610
References: Study published in JAMA Network Open
Keywords: Attention deficit hyperactivity disorder, Pediatrics